Edition:
India

Opiant Pharmaceuticals Inc (OPNT.OQ)

OPNT.OQ on NASDAQ Stock Exchange Capital Market

20.60USD
19 Jan 2018
Change (% chg)

$0.19 (+0.93%)
Prev Close
$20.41
Open
$20.40
Day's High
$21.00
Day's Low
$20.40
Volume
2,264
Avg. Vol
18,524
52-wk High
$51.90
52-wk Low
$17.01

Select another date:

Wed, Jan 3 2018

BRIEF-Opiant Pharmaceuticals Receives About $5.3 Mln Of Cash From Exercise Of Outstanding Warrants

* OPIANT PHARMACEUTICALS RECEIVES APPROXIMATELY $5.3 MILLION OF CASH FROM EXERCISE OF OUTSTANDING WARRANTS Source text for Eikon: Further company coverage:

BRIEF-Opiant Pharma Reports Financial Developments Related To Narcan Nasal Spray For Opioid Overdose

* OPIANT PHARMACEUTICALS ANNOUNCES SIGNIFICANT FINANCIAL DEVELOPMENTS RELATED TO NARCAN® NASAL SPRAY FOR OPIOID OVERDOSE

BRIEF-Opiant Pharmaceuticals, Inc. Reports Qtrly ‍net Loss Per Common Share $2.77​

* OPIANT PHARMACEUTICALS, INC. REPORTS FISCAL FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Opiant pharmaceuticals says ‍may offer & sell its shares through Cantor Fitzgerald

* Opiant Pharmaceuticals says ‍may offer & sell through Cantor Fitzgerald its shares having aggregate offering price of up to $25 million - SEC filing​ Source text (http://bit.ly/2gQyRPi) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Opiant Pharmaceuticals files for mixed shelf of upto $150 mln

* Opiant Pharmaceuticals Inc files for mixed shelf of upto $150 million - sec filing ‍​ Source text : http://bit.ly/2gmIQz2 Further company coverage:

BRIEF-Opiant Pharmaceuticals reports Q4 loss per share $0.17‍​

* Opiant Pharmaceuticals Inc reports fiscal fourth quarter and full year 2017 financial results and provides corporate update

BRIEF-Titan Pharmaceuticals and Opiant Pharmaceuticals collaborate to explore a new approach to opioid use disorder treatment

* Titan Pharmaceuticals and Opiant Pharmaceuticals collaborate to explore a new approach to opioid use disorder treatment

BRIEF-Opiant Pharma, Titan Pharmac to explore new treatments for opioid abuse

* Opiant Pharmaceuticals and Titan Pharmaceuticals collaborate to explore a new approach to opioid use disorder treatment

BRIEF-Opiant Pharmaceuticals Inc provides an update on Narcan nasal spray

* Opiant Pharmaceuticals Inc provides an update on Narcan nasal spray

BRIEF-Opiant Pharmaceuticals says co and Torreya Partners entered into a supplemental engagement letter

* Opiant Pharmaceuticals Inc - ‍on September 8, co and Torreya Partners entered into a supplemental engagement letter effective September 7​

Select another date: